Azione CPMV MOSAIC IMMUNOENGINEERING, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Mosaic ImmunoEngineering, Inc.

Azioni

CPMV

US61945M1018

Mercato chiuso - OTC Markets
Altri mercati azionari
 20:18:57 24/04/2024 		Variaz. 5gg Var. 1 gen.
0,3131 USD +0,03% Grafico intraday di Mosaic ImmunoEngineering, Inc. -43,06% -47,82%
15/04 Mosaic ImmunoEngineering, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023 CI
28/03 Mosaic ImmunoEngineering, Inc. riceve una lettera di rescissione da CWRU CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K
Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)
Mosaic Immunoengineering, Inc. Announces Nicole Steinmetz, Ph.D., to Resign as A Member of the Board of Directors and Acting Chief Scientific Officer
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Mosaic ImmunoEngineering Inc. Auditor Raises 'Going Concern' Doubt
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Mosaic ImmunoEngineering Inc. Academic Collaborators Receives Grants Totaling $4.3 Million from NCI Focuses on its Novel Immuno-Oncology Platform
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Mosaic ImmunoEngineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione CPMV
  4. Notizie Mosaic ImmunoEngineering, Inc.
  5. Altre lingue